A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Autor: Philipp le Coutre, Véronique Bédoucha, Delphine Rea, Dennis Dong Hwan Kim, Elza Lomaia, Michael J. Mauro, Andre Abdo, Lynette Chee, Sergey Voloshin, Dong-Wook Kim, Laura Fogliatto, Paola Aimone, Yosuke Minami, Alex Allepuz, Mario Annunziata, Jane F. Apperley, Susanne Saussele, Jorge E. Cortes, Andreas Hochhaus, Naeem Chaudhri, Carla Boquimpani, Koji Sasaki, Sara Quenet, Timothy P. Hughes, Anna G. Turkina, Valentín García-Gutiérrez

Publikováno v: Blood

Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of disease biology and inadequate efficacy and/or safety of current

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68ea953c680d4e6fe9a23516537c5aa9
https://doi.org/10.1182/blood.2020009984

Poster: CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update

Autor: Delphine Réa, Andreas Hochhaus, Michael J. Mauro, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Jane F. Apperley, Jorge E. Cortes, Andre Abdo, Laura Marie Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Lynette Chee, Valentin García-Gutiérrez, Koji Sasaki, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Carla Boquimpani

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 22:S145

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1fb133b2aeaf6d7ce8df88e584eed0da
https://doi.org/10.1016/s2152-2650(22)00881-3

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Autor: Véronique Bédoucha, Norbert Gattermann, Philipp le Coutre, Prashanth Gopalakrishna, Jerald P. Radich, Weiping Deng, Susanne Saussele, Eibhlin Conneally, Nancy Krunic, Giuseppe Saglio, Andrzej Hellmann, Bruno Martino, Francis J. Giles, Valentín García-Gutiérrez, Tamás Masszi, David M. Ross, María Teresa Gómez Casares, Jesper Stentoft, Andreas Hochhaus

Publikováno v: Journal of Cancer Research and Clinical Oncology
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Ross, D M, Masszi, T, Gómez Casares, M T, Hellmann, A, Stentoft, J, Conneally, E, Garcia-Gutierrez, V, Gattermann, N, le Coutre, P D, Martino, B, Saussele, S, Giles, F J, Radich, J P, Saglio, G, Deng, W, Krunic, N, Bédoucha, V, Gopalakrishna, P & Hochhaus, A 2018, ' Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib : 96-week update of the ENESTfreedom study ', Journal of Cancer Research and Clinical Oncology, vol. 144, no. 5, pp. 945-954 . https://doi.org/10.1007/s00432-018-2604-x

Purpose: ENESTfreedom is evaluating treatment-free remission (TFR) following frontline nilotinib in patients with chronic myeloid leukemia (CML) in chronic phase. Following our primary analysis at 48 weeks, we here provide an updated 96-week analysis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee2d4ac03af448129196634e600efcb4
http://europepmc.org/articles/PMC5916993

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Autor: Véronique Bédoucha, Delphine Rea, Valentín García Gutiérrez, Naeem Chaudhri, Michael J. Mauro, Alex Allepuz, Sergey Voloshin, Philipp le Coutre, Laura Fogliatto, Koji Sasaki, Paola Aimone, Timothy P. Hughes, Anna G. Turkina, Andreas Hochhaus, Andre Abdo, Dong-Wook Kim, Carla Boquimpani, Lynette C.Y. Chee, Jorge E. Cortes, Elza Lomaia, Mario Annunziata, Yosuke Minami, Sarah Quenet, Jane F. Apperley, Susanne Saussele, Dennis Dong Hwan Kim

Publikováno v: Blood. 136:LBA-4

Introduction: Asciminib, unlike all approved TKIs that bind to the ATP site of the BCR-ABL1 oncoprotein, is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor with a new mechanism of action. BOS, an ATP-competitive TKI

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8e6be9edabc20823787b3ee3346898d6
https://doi.org/10.1182/blood-2020-143816

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

Autor: P. le Coutre, Giuseppe Saglio, Jerry Radich, Bruno Martino, Eibhlin Conneally, Wieslaw Wiktor-Jedrzejczak, Tamás Masszi, Véronique Bédoucha, Andrzej Hellmann, M.T. Gómez Casares, Weiping Deng, Francis J. Giles, Valentín García-Gutiérrez, Nancy Krunic, Norbert Gattermann, Susanne Saussele, Jesper Stentoft, Andreas Hochhaus, David M. Ross, Hans D. Menssen

Publikováno v: Leukemia
Hochhaus, A, Masszi, T, Giles, F J, Radich, J P, Ross, D M, Gomez Casares, M T, Hellmann, A, Stentoft, J, Conneally, E, Garcia-Gutierrez, V, Gattermann, N, Wiktor-Jedrzejczak, W, le Coutre, P D, Martino, B, Saussele, S, Menssen, H D, Deng, W, Krunic, N, Bedoucha, V & Saglio, G 2017, ' Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase : results from the ENESTfreedom study ', Leukemia, vol. 31, no. 7, pp. 1525-1531 . https://doi.org/10.1038/leu.2017.63
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7f978aac8518e358eddf83deebc3149
https://pubmed.ncbi.nlm.nih.gov/28218239